Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 273

1.

Current status of use of big data and artificial intelligence in RMDs: a systematic literature review informing EULAR recommendations.

Kedra J, Radstake T, Pandit A, Baraliakos X, Berenbaum F, Finckh A, Fautrel B, Stamm TA, Gomez-Cabrero D, Pristipino C, Choquet R, Servy H, Stones S, Burmester G, Gossec L.

RMD Open. 2019 Jul 18;5(2):e001004. doi: 10.1136/rmdopen-2019-001004. eCollection 2019.

PMID:
31413871
2.

Impact of comorbidities and functional impairment on 5-year loss of health utility in patients with lower-limb osteoarthritis in the KHOALA cohort.

Omorou AY, Achit H, Wieczorek M, Pouchot J, Fautrel B, Rat AC, Guillemin F.

Qual Life Res. 2019 Jul 4. doi: 10.1007/s11136-019-02243-4. [Epub ahead of print]

PMID:
31273625
3.

[It is time to reconcile systemic juvenile idiopathic arthritis and adult-onset Still's disease].

Jamilloux Y, Georgin-Lavialle S, Sève P, Belot A, Fautrel B.

Rev Med Interne. 2019 Jun 17. pii: S0248-8663(19)30522-3. doi: 10.1016/j.revmed.2019.06.001. [Epub ahead of print] French. No abstract available.

PMID:
31221454
4.

Cost-effectiveness of five different anti-tumour necrosis factor tapering strategies in rheumatoid arthritis: a modelling study.

Verhoef LM, Bos D, van den Ende C, van den Hoogen F, Fautrel B, Hulscher ME, Kievit W, den Broeder AA.

Scand J Rheumatol. 2019 Jun 21:1-9. doi: 10.1080/03009742.2019.1613674. [Epub ahead of print]

PMID:
31220991
5.

Knowledge of and expectations about functional restoration programs for chronic low back pain: A mirror survey of 150 patients and 80 physicians in 2017.

Letellier P, Bailly F, Assadourian M, Potel A, Foltz V, Ascione S, Morardet L, Le Ralle M, Fautrel B, Dupeyron A, Ibrahim-Nasser N, Griffoul-Espitalier I, Duplan B, Beaudreuil J, Gossec L.

Joint Bone Spine. 2019 Jun 16. pii: S1297-319X(19)30093-4. doi: 10.1016/j.jbspin.2019.06.002. [Epub ahead of print] No abstract available.

PMID:
31216489
6.

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial.

Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, Zhu B, Quebe AK, Gaich CL, Zhang X, Dickson CL, Schlichting DE, Patel H, Durand F, Emery P.

J Clin Med. 2019 Jun 12;8(6). pii: E831. doi: 10.3390/jcm8060831.

7.

Alcohol is not the missing link between Porphyromonas gingivalis-related periodontitis and radiological progression in early rheumatoid arthritis: comment on 'Porphyromonas gingivalis experimentally induces periodontitis and an anti-CCP2-associated arthritis in the rat'.

Hillion J, Bellier A, Romand X, Fautrel B, Mariette X, Sagéloli F, Baillet A, Gaudin P.

Ann Rheum Dis. 2019 Jun 14. pii: annrheumdis-2019-215603. doi: 10.1136/annrheumdis-2019-215603. [Epub ahead of print] No abstract available.

PMID:
31201174
8.

Developing a Preliminary Definition and Domains of Flare in Knee and Hip Osteoarthritis (OA): Consensus Building of the Flare-in-OA OMERACT Group.

Guillemin F, Ricatte C, Barcenilla-Wong A, Schoumacker A, Cross M, Alleyrat C, Buttel T, Cembalo M, Manseur H, Urban H, Fautrel B, Conaghan PG, Hawker G, Rutherford C, March L, Spitz E, Hunter DJ.

J Rheumatol. 2019 May 15. pii: jrheum.181085. doi: 10.3899/jrheum.181085. [Epub ahead of print]

PMID:
31092709
9.

Tapering without relapse in rheumatoid arthritis patients with high TNF blocker concentrations: data from STRASS study.

Marotte H, Rinaudo-Gaujous M, Petiet C, Fautrel B, Paul S.

Ann Rheum Dis. 2019 May 2. pii: annrheumdis-2019-215546. doi: 10.1136/annrheumdis-2019-215546. [Epub ahead of print] No abstract available.

PMID:
31048287
10.

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis.

Tanaka Y, Fautrel B, Keystone EC, Ortmann RA, Xie L, Zhu B, Issa M, Patel H, Gaich CL, de Bono S, Rooney TP, Taylor PC.

Ann Rheum Dis. 2019 Jul;78(7):890-898. doi: 10.1136/annrheumdis-2018-214529. Epub 2019 Apr 30.

11.

Health resource use and costs of symptomatic knee and/or hip osteoarthritis.

Salmon JH, Rat AC, Achit H, Ngueyon-Sime W, Gard C, Guillemin F, Jolly D, Fautrel B.

Osteoarthritis Cartilage. 2019 Jul;27(7):1011-1017. doi: 10.1016/j.joca.2019.03.005. Epub 2019 Mar 25.

PMID:
30922982
12.

Similar alteration for mental and physical aspects in health-related quality of life over 5 to 8 years in 1347 patients with early arthritis and early inflammatory back pain.

Puyraimond-Zemmour D, Granger B, Molto A, Gaujoux-Viala C, Guillemin F, Ruyssen-Witrand A, Dougados M, Fautrel B, Gossec L.

Arthritis Res Ther. 2019 Feb 19;21(1):63. doi: 10.1186/s13075-019-1841-y.

13.

Adult-onset Still's disease biological treatment strategy may depend on the phenotypic dichotomy.

Vercruysse F, Barnetche T, Lazaro E, Shipley E, Lifermann F, Balageas A, Delbrel X, Fautrel B, Richez C, Schaeverbeke T, Truchetet ME.

Arthritis Res Ther. 2019 Feb 12;21(1):53. doi: 10.1186/s13075-019-1838-6.

14.

Effects of concomitant glucocorticoids in TOZURA, a common-framework study programme of subcutaneous tocilizumab in rheumatoid arthritis.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Devenport J, Pethö-Schramm A.

Rheumatology (Oxford). 2019 Jun 1;58(6):1056-1064. doi: 10.1093/rheumatology/key393.

15.

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial.

Rosenzwajg M, Lorenzon R, Cacoub P, Pham HP, Pitoiset F, El Soufi K, RIbet C, Bernard C, Aractingi S, Banneville B, Beaugerie L, Berenbaum F, Champey J, Chazouilleres O, Corpechot C, Fautrel B, Mekinian A, Regnier E, Saadoun D, Salem JE, Sellam J, Seksik P, Daguenel-Nguyen A, Doppler V, Mariau J, Vicaut E, Klatzmann D.

Ann Rheum Dis. 2019 Feb;78(2):209-217. doi: 10.1136/annrheumdis-2018-214229. Epub 2018 Nov 24.

PMID:
30472651
16.

Hormonal Risk Factors for Osteoporosis: Different Profile Among Antipsychotics.

Raffin M, Bonnot O, Giannitelli M, Xavier J, Bodeau N, Bibrac B, Leban M, Fautrel B, Menard ML, Consoli A, Cohen D.

J Child Adolesc Psychopharmacol. 2018 Nov 13. doi: 10.1089/cap.2017.0158. [Epub ahead of print]

PMID:
30421978
17.

Incidence and risk factors for adalimumab and infliximab anti-drug antibodies in rheumatoid arthritis: A European retrospective multicohort analysis.

Quistrebert J, Hässler S, Bachelet D, Mbogning C, Musters A, Tak PP, Wijbrandts CA, Herenius M, Bergstra SA, Akdemir G, Johannesson M, Combe B, Fautrel B, Chollet-Martin S, Gleizes A, Donnellan N, Deisenhammer F, Davidson J, Hincelin-Mery A, Dönnes P, Fogdell-Hahn A, De Vries N, Huizinga T, Abugessaisa I, Saevarsdottir S, Hacein-Bey-Abina S, Pallardy M, Broët P, Mariette X; ABIRISK Consortium.

Semin Arthritis Rheum. 2019 Jun;48(6):967-975. doi: 10.1016/j.semarthrit.2018.10.006. Epub 2018 Oct 12.

PMID:
30420245
18.

Update of French society for rheumatology recommendations for managing rheumatoid arthritis.

Daien C, Hua C, Gaujoux-Viala C, Cantagrel A, Dubremetz M, Dougados M, Fautrel B, Mariette X, Nayral N, Richez C, Saraux A, Thibaud G, Wendling D, Gossec L, Combe B.

Joint Bone Spine. 2019 Mar;86(2):135-150. doi: 10.1016/j.jbspin.2018.10.002. Epub 2018 Oct 10.

PMID:
30315988
19.

Detection of flares by decrease in physical activity, collected using wearable activity trackers, in rheumatoid arthritis or axial spondyloarthritis: an application of Machine-Learning analyses in rheumatology.

Gossec L, Guyard F, Leroy D, Lafargue T, Seiler M, Jacquemin C, Molto A, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Fautrel B, Servy H.

Arthritis Care Res (Hoboken). 2018 Sep 22. doi: 10.1002/acr.23768. [Epub ahead of print]

PMID:
30242992
20.

Use of Wearable Activity Trackers to Improve Physical Activity Behavior in Patients With Rheumatic and Musculoskeletal Diseases: A Systematic Review and Meta-Analysis.

Davergne T, Pallot A, Dechartres A, Fautrel B, Gossec L.

Arthritis Care Res (Hoboken). 2019 Jun;71(6):758-767. doi: 10.1002/acr.23752. Epub 2019 Apr 23.

PMID:
30221489
21.

Mechanisms, biomarkers and targets for adult-onset Still's disease.

Feist E, Mitrovic S, Fautrel B.

Nat Rev Rheumatol. 2018 Oct;14(10):603-618. doi: 10.1038/s41584-018-0081-x. Review.

PMID:
30218025
22.

Reply to the comment of Alkan Melikoglu 'Joint manifestations can provide diagnostic clues in Morquio syndrome, a case report'.

Mitrovic S, Gouze H, Schaeverbeke T, Gossec L, Fautrel B.

Joint Bone Spine. 2019 Jan;86(1):123-124. doi: 10.1016/j.jbspin.2018.06.016. Epub 2018 Jul 29. No abstract available.

PMID:
30064008
23.

Cost Effectiveness of Intra-Articular Hyaluronic Acid and Disease-Modifying Drugs in Knee Osteoarthritis.

Salmon JH, Rat AC, Charlot-Lambrecht I, Eschard JP, Jolly D, Fautrel B.

Pharmacoeconomics. 2018 Nov;36(11):1321-1331. doi: 10.1007/s40273-018-0695-5. Review.

PMID:
30047014
24.

Ability of disease-modifying antirheumatic drugs to prevent or delay rheumatoid arthritis onset: a systematic literature review and meta-analysis.

Hilliquin S, Hugues B, Mitrovic S, Gossec L, Fautrel B.

Ann Rheum Dis. 2018 Aug;77(8):1099-1106. doi: 10.1136/annrheumdis-2017-212612. Epub 2018 Jun 8.

PMID:
29884751
25.

Effect of cumulative exposure to corticosteroid and DMARD on radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort.

Louveau B, De Rycke Y, Lafourcade A, Saraux A, Guillemin F, Tubach F, Fautrel B, Hajage D.

Rheumatology (Oxford). 2018 Sep 1;57(9):1563-1573. doi: 10.1093/rheumatology/key122.

PMID:
29796624
26.

Increased severity and epidermal alterations in persistent versus evanescent skin lesions in adult-onset Still disease.

Zuelgaray E, Battistella M, Sallé de Chou C, Vignon-Pennamen MD, Rybojad M, Petit A, Cordoliani F, Chasset F, Bachmeyer C, Fardet L, Fautrel B, Cacoub P, Lipsker D, Bagot M, Bouaziz JD.

J Am Acad Dermatol. 2018 Nov;79(5):969-971. doi: 10.1016/j.jaad.2018.05.020. Epub 2018 May 19. No abstract available.

PMID:
29787836
27.

Moderate alcohol consumption is associated with increased radiological progression in women, but not in men, with early rheumatoid arthritis: results from the ESPOIR cohort (Étude et Suivi des Polyarthrites Indifférenciées Récentes).

Sageloli F, Quesada JL, Fautrel B, Salliot C, Gaudin P, Baillet A.

Scand J Rheumatol. 2018 Nov;47(6):440-446. doi: 10.1080/03009742.2018.1437216. Epub 2018 May 18.

PMID:
29774784
28.

Complications of adult-onset Still's disease and their management.

Mitrovic S, Fautrel B.

Expert Rev Clin Immunol. 2018 May;14(5):351-365. doi: 10.1080/1744666X.2018.1465821. Epub 2018 Apr 26.

PMID:
29658384
29.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Jun 1;57(6):1129. doi: 10.1093/rheumatology/key116. No abstract available.

30.

Call for action: how to improve use of patient-reported outcomes to guide clinical decision making in rheumatoid arthritis.

Fautrel B, Alten R, Kirkham B, de la Torre I, Durand F, Barry J, Holzkaemper T, Fakhouri W, Taylor PC.

Rheumatol Int. 2018 Jun;38(6):935-947. doi: 10.1007/s00296-018-4005-5. Epub 2018 Mar 21. Review.

31.

Efficacy and safety of canakinumab in patients with Still's disease: exposure-response analysis of pooled systemic juvenile idiopathic arthritis data by age groups.

Feist E, Quartier P, Fautrel B, Schneider R, Sfriso P, Efthimiou P, Cantarini L, Lheritier K, Leon K, Karyekar CS, Speziale A.

Clin Exp Rheumatol. 2018 Jul-Aug;36(4):668-675. Epub 2018 Mar 2.

32.

Diabetes at the time of rheumatoid arthritis diagnosis is an independent predictor of pejorative outcomes: Data from the early arthritis ESPOIR cohort.

Daïen CI, Sellam J, Rincheval N, Fautrel B, Saraux A, Morel J, Berenbaum F, Daurès JP, Combe B.

Joint Bone Spine. 2018 Dec;85(6):773-775. doi: 10.1016/j.jbspin.2018.02.004. Epub 2018 Feb 23. No abstract available.

PMID:
29481873
33.

Cost-effectiveness analysis of strategies using new immunological diagnostic tests of latent tuberculosis infection before TNF-blockers therapy.

Freund R, Granger B, Francois C, Carcelain G, Ravaud P, Mariette X, Fautrel B.

Presse Med. 2018 Feb;47(2):e9-e13. doi: 10.1016/j.lpm.2017.09.029. Epub 2018 Feb 23.

PMID:
29478790
34.

Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still's disease.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA, Martin T, Hellmich B, Lamprecht P, Schulze-Koops H, Courvoisier DS, Sleight A, Schiffrin EJ.

Ann Rheum Dis. 2018 Jun;77(6):840-847. doi: 10.1136/annrheumdis-2017-212608. Epub 2018 Feb 22.

35.

Phrasing of the patient global assessment in the rheumatoid arthritis ACR/EULAR remission criteria: an analysis of 967 patients from two databases of early and established rheumatoid arthritis patients.

Gossec L, Kirwan JR, de Wit M, Balanescu A, Gaujoux-Viala C, Guillemin F, Rat AC, Saraux A, Fautrel B, Kvien TK, Dougados M; RAID investigators.

Clin Rheumatol. 2018 Jun;37(6):1503-1510. doi: 10.1007/s10067-018-3998-1. Epub 2018 Feb 21.

PMID:
29468340
36.

Effect of biologics on fatigue in psoriatic arthritis: A systematic literature review with meta-analysis.

Reygaerts T, Mitrovic S, Fautrel B, Gossec L.

Joint Bone Spine. 2018 Jul;85(4):405-410. doi: 10.1016/j.jbspin.2018.01.011. Epub 2018 Feb 13.

PMID:
29452303
37.

Therapeutic strategy for rheumatoid arthritis patients who have achieved remission.

Fautrel B.

Joint Bone Spine. 2018 Dec;85(6):679-685. doi: 10.1016/j.jbspin.2018.02.002. Epub 2018 Feb 13.

PMID:
29452300
38.

Report of two cases of tocilizumab induced recurrent meningitis or meningoencephalitis.

Richebé P, Bailly F, Mariani LL, Pena PS, Pedespan JM, Fautrel B.

Joint Bone Spine. 2018 Oct;85(5):643-644. doi: 10.1016/j.jbspin.2018.01.002. Epub 2018 Jan 31. No abstract available.

PMID:
29366968
39.

Physical Activity Assessment Using an Activity Tracker in Patients with Rheumatoid Arthritis and Axial Spondyloarthritis: Prospective Observational Study.

Jacquemin C, Servy H, Molto A, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Fautrel B, Gossec L.

JMIR Mhealth Uhealth. 2018 Jan 2;6(1):e1. doi: 10.2196/mhealth.7948.

40.

Subcutaneous tocilizumab in rheumatoid arthritis: findings from the common-framework phase 4 study programme TOZURA conducted in 22 countries.

Choy E, Caporali R, Xavier R, Fautrel B, Sanmarti R, Bao M, Bernasconi C, Pethö-Schramm A.

Rheumatology (Oxford). 2018 Mar 1;57(3):499-507. doi: 10.1093/rheumatology/kex443. Erratum in: Rheumatology (Oxford). 2018 Jun 1;57(6):1129.

41.

Dosing down with biologic therapies: a systematic review and clinicians' perspective.

Edwards CJ, Fautrel B, Schulze-Koops H, Huizinga TWJ, Kruger K.

Rheumatology (Oxford). 2018 Mar 1;57(3):589. doi: 10.1093/rheumatology/kex503. No abstract available.

42.

Risk of losing remission, low disease activity or radiographic progression in case of bDMARD discontinuation or tapering in rheumatoid arthritis: systematic analysis of the literature and meta-analysis.

Henaux S, Ruyssen-Witrand A, Cantagrel A, Barnetche T, Fautrel B, Filippi N, Lukas C, Raffeiner B, Rossini M, Degboé Y, Constantin A.

Ann Rheum Dis. 2018 Apr;77(4):515-522. doi: 10.1136/annrheumdis-2017-212423. Epub 2017 Nov 29.

PMID:
29187350
43.

Prevalence of pelvic Paget's disease of bone in France.

Mazières B, Coste J, Euller-Ziegler L, Fardellone P, Fautrel B, Pouchot J, Rat AC, Roux CH, Saraux A, Verrouil E, Guillemin F.

Bone. 2018 Feb;107:143-144. doi: 10.1016/j.bone.2017.11.017. Epub 2017 Nov 22. No abstract available.

PMID:
29175270
44.

Sustainability of TNF-blocker tapering in rheumatoid arthritis over 3 years: long-term follow-up of the STRASS (Spacing of TNF-blocker injections in Rheumatoid ArthritiS Study) randomised controlled trial.

Sigaux J, Bailly F, Hajage D, Mariette X, Morel J, Gandjbakhch F, Foltz V, Gossec L, Tubach F, Fautrel B.

RMD Open. 2017 Sep 12;3(2):e000474. doi: 10.1136/rmdopen-2017-000474. eCollection 2017.

45.

Influence of disease activity on RA treatment choices in countries with restricted access to expensive, innovative drugs: a discrete choice experiment among rheumatologists.

Hifinger M, Hiligsmann M, Ramiro S, Watson V, Berghea F, Péntek M, Keat A, Severens JL, Fautrel B, Boonen A.

RMD Open. 2017 Sep 4;3(2):e000453. doi: 10.1136/rmdopen-2017-000453. eCollection 2017.

46.

Access criteria for anti-TNF agents in spondyloarthritis: influence on comparative 1-year cost-effectiveness estimates.

Harvard S, Guh D, Bansback N, Richette P, Saraux A, Fautrel B, Anis A.

Cost Eff Resour Alloc. 2017 Sep 7;15:20. doi: 10.1186/s12962-017-0081-8. eCollection 2017.

47.

Flares assessed weekly in patients with rheumatoid arthritis or axial spondyloarthritis and relationship with physical activity measured using a connected activity tracker: a 3-month study.

Jacquemin C, Molto A, Servy H, Sellam J, Foltz V, Gandjbakhch F, Hudry C, Mitrovic S, Granger B, Fautrel B, Gossec L.

RMD Open. 2017 Jun 29;3(1):e000434. doi: 10.1136/rmdopen-2017-000434. eCollection 2017.

48.

Optimal methotrexate dose is associated with better clinical outcomes than non-optimal dose in daily practice: results from the ESPOIR early arthritis cohort.

Gaujoux-Viala C, Rincheval N, Dougados M, Combe B, Fautrel B.

Ann Rheum Dis. 2017 Dec;76(12):2054-2060. doi: 10.1136/annrheumdis-2017-211268. Epub 2017 Sep 2.

PMID:
28866645
49.

Drivers of patient global assessment in patients with rheumatoid arthritis who are close to remission: an analysis of 1588 patients.

Ferreira RJO, Dougados M, Kirwan JR, Duarte C, de Wit M, Soubrier M, Fautrel B, Kvien TK, da Silva JAP, Gossec L; CoimbRA investigators, RAID investigators and COMEDRA investigators.

Rheumatology (Oxford). 2017 Sep 1;56(9):1573-1578. doi: 10.1093/rheumatology/kex211.

PMID:
28859325
50.

Content and Construct Validity, Reliability, and Responsiveness of the Rheumatoid Arthritis Flare Questionnaire: OMERACT 2016 Workshop Report.

Bartlett SJ, Barbic SP, Bykerk VP, Choy EH, Alten R, Christensen R, den Broeder A, Fautrel B, Furst DE, Guillemin F, Hewlett S, Leong AL, Lyddiatt A, March L, Montie P, Pohl C, Scholte Voshaar M, Woodworth TG, Bingham CO 3rd.

J Rheumatol. 2017 Oct;44(10):1536-1543. doi: 10.3899/jrheum.161145. Epub 2017 Aug 15.

Supplemental Content

Loading ...
Support Center